Eli Lilly (NYSE: LLY) has become a giant in what may be a $100 billion market a few years from now. I'm talking about the world of weight loss drugs.

Doctors have been prescribing Mounjaro and the newly approved Zepbound to patients aiming to shed pounds, and that's brought in billions in revenue to the pharma giant. These drugs work by acting on glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), two hormone pathways involved in the digestion process.

But in the coming years, Lilly could face competition from a young biotech that was founded in 2012 called Viking Therapeutics (NASDAQ: VKTX). This new kid on the block is developing a drug candidate that works in the same way as the Lilly drugs and recently reported excellent clinical trial data.

Continue reading

Source Fool.com